Anzemet (dolasetron mesylate): Drug Safety Communication – Reports of Abnormal Heart Rhythms

Audience: Oncology, Cardiology ISSUE: FDA notified healthcare professionals that a contraindication is being added to the prescribing information advising that the injection form of Anzemet (dolasetron mesylate) should no longer be used to prevent…



No related posts.